Search Results

eGenesis and PorMedTec have successfully produced genetically engineered porcine donors in Japan for use in transplantation.

eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

eGenesis and OrganOx today announced the successful completion of an extracorporeal perfusion of a brain-dead research donor using a genetically engineered porcine liver.

eGenesis, a biotechnology company developing human-compatible (HuCo™) organs for the treatment of organ failure, today announced publication in the journal Nature of long-term survival data from a proof-of-concept study evaluating engineered porcine donor kidneys transplanted into a cynomolgus macaque model.

eGenesis will present new data and host a symposium during the IPITA (International Pancreas and Islet Transplant Association), IXA (International Xenotransplantation Association), and CTRMS (Cell Transplant and Regenerative Medicine Society) joint congress, held in San Diego, October 26-29, 2023.

eGenesis, Inc. (“eGenesis”) and Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that they have entered into a collaborative research agreement under which eGenesis will gain access to Eledon’s anti-CD40L antibody candidate, tegoprubart, for eGenesis’ ongoing preclinical research and development studies of human-compatible organs and cells for the treatment of organ failure.

eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer.

eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, will present new data during the American Transplant Congress 2023, held June 3 – June 7, 2023 in San Diego, CA.

Karius® and eGenesis, Inc. a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced a partnership through which the two companies will develop infectious disease diagnostics for xenotransplantation initially from porcine to primates and ultimately to humans.

eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, announced the publication of a paper in the journal Nature Communications highlighting novel findings from the largest cohort of long-term non-human primate recipients of porcine kidney xenotransplantation to date.